RxDoctor Payments DataLook up a doctor →

Osler Jay Guzon, MD

Cardiovascular Disease · Saint Louis, MONPI 1285683888

Payments from drug & device makers

$210,851in general payments, 2019–2025

Across 933 payments — averaging $225.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$62K
  • Novo Nordisk$53K
  • AstraZeneca$47K
  • Lilly USA, LLC$25K
  • Bayer$10K
  • Biotronik Inc.$2K
  • plus $13K from 37 others

What the payments were for

  • Consulting fees$10,7585%
  • Speaking & faculty fees$153,95373%
  • Travel & lodging$24,79112%
  • Food & beverage$21,27610%
  • Education$730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$210,851 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$131,649
Medicare patients
757
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol583$472,124
EliquisApixaban502$461,224
EntrestoSacubitril/Valsartan221$218,486
OzempicSemaglutide151$193,006
JardianceEmpagliflozin152$144,661
XareltoRivaroxaban151$132,512
KerendiaFinerenone51$48,779
VascepaIcosapent Ethyl87$43,857
Repatha SureclickEvolocumab48$31,766
BrilintaTicagrelor30$25,259
TrulicityDulaglutide16$15,358
MultaqDronedarone Hcl15$11,933
DapagliflozinDapagliflozin Propanediol21$9,906
Praluent PenAlirocumab14$8,092
CorlanorIvabradine Hcl12$7,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$46,771$497,384613 claims
PfizerEliquis$86$461,224502 claims
NovartisEntresto$1,042$218,486221 claims
Novo NordiskOzempic$52,508$193,006151 claims
Boehringer IngelheimJardiance$61,779$144,661152 claims
Johnson & JohnsonXarelto$1,605$132,512151 claims
BayerKerendia$9,779$48,77951 claims
Lilly USA, LLCTrulicity$25,081$15,35816 claims
Sanofi-aventis U.S. LLCMultaq$161$11,93315 claims
AmgenCorlanor$1,577$7,97112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →